297 related articles for article (PubMed ID: 26616565)
1. Emerging immunotherapy in pediatric lymphoma.
Erker C; Harker-Murray P; Burke MJ
Future Oncol; 2016 Jan; 12(2):257-70. PubMed ID: 26616565
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
3. Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas.
Kasenda B; Kühnl A; Chau I
Expert Rev Hematol; 2016; 9(2):123-35. PubMed ID: 26581237
[TBL] [Abstract][Full Text] [Related]
4. Current and future immunotherapeutic approaches in Hodgkin lymphoma.
Bröckelmann PJ; Borchmann P; Engert A
Leuk Lymphoma; 2016 Sep; 57(9):2014-24. PubMed ID: 27243940
[TBL] [Abstract][Full Text] [Related]
5. Biologic agents in the management of Hodgkin lymphoma.
Rashidi A; Bartlett NL
J Natl Compr Canc Netw; 2015 May; 13(5):587-96. PubMed ID: 25964642
[TBL] [Abstract][Full Text] [Related]
6. Targeting indolent non-Hodgkin lymphoma.
Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
[TBL] [Abstract][Full Text] [Related]
7. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
Hochberg J; El-Mallawany NK; Cairo MS
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
[TBL] [Abstract][Full Text] [Related]
8. An Update on the Use of Immunotherapy in the Treatment of Lymphoma.
Marron TU; Kalac M; Brody J
Curr Hematol Malig Rep; 2017 Aug; 12(4):282-289. PubMed ID: 28735365
[TBL] [Abstract][Full Text] [Related]
9. Novel immunotherapies in lymphoid malignancies.
Batlevi CL; Matsuki E; Brentjens RJ; Younes A
Nat Rev Clin Oncol; 2016 Jan; 13(1):25-40. PubMed ID: 26525683
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
Sikaria S; Aldoss I; Akhtari M
Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
[TBL] [Abstract][Full Text] [Related]
11. Noncellular Immune Therapies for Non-Hodgkin Lymphoma.
Herrera AF
Hematol Oncol Clin North Am; 2019 Aug; 33(4):707-725. PubMed ID: 31229164
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies.
Tun AM; Ansell SM
Cancer Treat Rev; 2020 Aug; 88():102042. PubMed ID: 32521386
[TBL] [Abstract][Full Text] [Related]
13. Agents in Development for Childhood Acute Lymphoblastic Leukemia.
Maloney KW; Gore L
Paediatr Drugs; 2018 Apr; 20(2):111-120. PubMed ID: 29143289
[TBL] [Abstract][Full Text] [Related]
14. Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation.
Siddiqi T; Rosen ST
Oncology (Williston Park); 2015 Apr; 29(4):299-308. PubMed ID: 25920929
[TBL] [Abstract][Full Text] [Related]
15. Advances in targeted therapy for malignant lymphoma.
Wang L; Qin W; Huo YJ; Li X; Shi Q; Rasko JEJ; Janin A; Zhao WL
Signal Transduct Target Ther; 2020 Mar; 5(1):15. PubMed ID: 32296035
[TBL] [Abstract][Full Text] [Related]
16. Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies.
Kebriaei P; Poon ML
Curr Hematol Malig Rep; 2015 Jun; 10(2):76-85. PubMed ID: 25899862
[TBL] [Abstract][Full Text] [Related]
17. Review of antibody-based immunotherapy in the treatment of non-Hodgkin lymphoma and patterns of use.
Cannon AC; Loberiza FR
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):129-38. PubMed ID: 25176473
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
Barth MJ; Chu Y; Hanley PJ; Cairo MS
Br J Haematol; 2016 May; 173(4):597-616. PubMed ID: 27062282
[TBL] [Abstract][Full Text] [Related]
19. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
20. CD30 as a therapeutic target for lymphoma.
Schirrmann T; Steinwand M; Wezler X; Ten Haaf A; Tur MK; Barth S
BioDrugs; 2014 Apr; 28(2):181-209. PubMed ID: 24043362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]